Suboptimal Treatment of Inflammatory Bowel Disease in Clinical Practice

Author(s):

Silvio Danese, MD, PhD; Bruce Sands, MD, and Jean-Frederic Colombel, MD highlight the common practice in many community settings of treating inflammatory bowel disease with corticosteroids, with or without 5-aminosalicylic acid, and cycling patients through this regimen for prolonged periods, while emphasizing the significant impact and toxicities associated with this treatment approach.

EP: 1.Treat-to-target in Inflammatory Bowel Disease

EP: 2.Recommended Targets When Treating Ulcerative Colitis/Crohn’s Disease in Clinic

EP: 3.Transmural Healing and Monitoring in Ulcerative Colitis and Crohn’s Disease

EP: 4.Implementing Treat to Target in the Long-term in Inflammatory Bowel Disease

Now Viewing

EP: 5.Suboptimal Treatment of Inflammatory Bowel Disease in Clinical Practice

EP: 6.Unmet Needs and Starting Advanced Treatment in Inflammatory Bowel Disease

EP: 7.Considerations for Choosing Advanced Treatments and Setting Patient Expectations

EP: 8.Combination Therapy in Inflammatory Bowel Disease

EP: 9.Measuring Patient Satisfaction with Inflammatory Bowel Disease Treatments and Communication Regarding Treatment Changes

In many community practices, IBD is treated with corticosteroids with or without 5-ASA, and patients are cycled through this regimen for a long time. How does this approach impact long-term patient outcomes?